Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

44.56USD
30 Jan 2015
Change (% chg)

$-1.36 (-2.96%)
Prev Close
$45.92
Open
$45.26
Day's High
$45.30
Day's Low
$44.54
Volume
270,372
Avg. Vol
239,246
52-wk High
$49.10
52-wk Low
$37.85

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $94,966.55
Shares Outstanding(Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.86

Financials

  NVO.N Industry Sector
P/E (TTM): 29.83 37.76 38.54
EPS (TTM): 1.49 -- --
ROI: 62.12 18.79 18.06
ROE: 67.46 19.44 18.83
Search Stocks

UPDATE 2-Novo bullish on 2015 goals, untroubled by U.S. competition

COPENHAGEN, Jan 30 - Danish insulin maker Novo Nordisk said it not expect significant pressure this year on its business in the United States, where rivals are fighting for its market share, after reporting on Friday a stronger fourth quarter than expected.

30 Jan 2015

Novo Nordisk CEO says sees little U.S. pricing pressures

COPENHAGEN, Jan 30 - Novo Nordisk does not expect pressure on prices for its drugs in the United States, the world's largest pharmaceutical market, Chief Executive Lars Rebien Sorensen told reporters on a conference call on Friday.

30 Jan 2015

NORDIC STOCKS - Factors to watch on Jan 30

STOCKHOLM, Jan 30 - The following stocks may be affected by newspaper reports and other factors on Friday:

30 Jan 2015

RPT-Novo Nordisk keeps 2015 guidance after strong Q4

COPENHAGEN, Jan 30 - Denmark's Novo Nordisk maintained its financial guidance for 2015, giving a more detailed number for its sales growth, after a stronger fourth quarter than expected.

30 Jan 2015

Novo Nordisk keeps 2015 guidance after strong Q4

COPENHAGEN, Jan 30 - Denmark's Novo Nordisk maintained its financial guidance for 2015, giving a more detailed number for its sales growth, after a stronger fourth quarter than expected.

30 Jan 2015

Novo Nordisk to launch obesity treatment in EU markets in 2015

COPENHAGEN, Jan 23 - Novo Nordisk, the world's biggest insulin maker, said on late Thursday it has received a positive opinion from the European regulatory authorities for its obesity treatment Saxenda.

23 Jan 2015

BRIEF-Novo Nordisk says Switzerland first country to launch Xultophy

Jan 19 - Novo Nordisk A/S : ** Says Switzerland first country to launch Xultophy (IDegLira) for people with type 2 diabetes ** Says expects to make Xultophy available in other countries throughout Europe in 2015 Source text for Eikon:

19 Jan 2015

Novo Nordisk to promote drug to treat obesity in United States

COPENHAGEN - Danish pharmaceutical group Novo Nordisk plans to use 500 of its 3,000-strong sales force in the United States to promote its new obesity drug, executive vice president Jakob Riis told Reuters on Monday.

29 Dec 2014

Novo Nordisk to promote drug to treat obesity in United States

COPENHAGEN, Dec 29 - Danish pharmaceutical group Novo Nordisk plans to use 500 of its 3,000-strong sales force in the United States to promote its new obesity drug, executive vice president Jakob Riis told Reuters on Monday.

29 Dec 2014

Novo Nordisk CEO sees short-term challenges to growth - paper

COPENHAGEN, Dec 27 - Novo Nordisk, the world's biggest insulin maker, is confident about its long-term growth plans but needs to secure approval for its new long-acting insulin Tresiba in the United States, its chief executive said in a newspaper interview on Saturday.

27 Dec 2014

Competitors

  Price Chg
Sanofi SA (SASY.PA) €82.00 -0.26
Eli Lilly and Co (LLY.N) $72.00 -0.11

Earnings vs. Estimates

Search Stocks